BOSTON January 3, 2019-The Center for Information and Study on Clinical Research Participation (CISCRP), a Boston-based nonprofit organization announces that it has launched a virtual fitness challenge to raise awareness and recognize people who participate in clinical trials. This novel event – dubbed the Medical Hero Appreci-a-thon – encourages patients, professionals and the public to show their support.
A large and growing body of research shows that general public awareness and understanding of the important, courageous and altruistic role of clinical trial participants is low. An estimated 1.8 million people volunteered to participate in clinical trials regulated by the Food and Drug Administration in 2018. Without these volunteers, the development of new medical treatments and the advancement of public health would not occur.
CISCRP invites the public, patients, health and clinical research professionals to “go the distance” and show their support by registering and participating in a fitness challenge that follows a virtual Route 66 racecourse. Participants can conveniently log any and all forms of physical activity to advance along the virtual route each day. Proceeds from the virtual fitness challenge will support educational programs designed to help patients and their families better navigate the clinical research experience.
Since 2003, CISCRP has been producing educational and awareness-building programs and events nationwide including AWARE-for-ALL and the Medical Heroes 5K run/walk.
“We’ve collaborated with the National Institutes of Health and the private sector to develop a number of awareness building campaigns including ‘Behind Every Medicine’, ‘Medical Heroes in Everyday Places,’ and the ‘MT Pharmacy’ during the past 15 years,” said Ken Getz, CISCRP’s founder. “With the new Medical Hero Appreci-a-thon, CISCRP hopes to attract and raise awareness and active support among a much larger audience.”
The Med Hero Appreci-a-thon challenge officially begins on February 1, 2019 and runs through February 28. CISCRP has produced this event in collaboration with Racery, an organization that designs platforms to power virtual fitness activities. Registration is now open and participants can register at www.MedHero.org.
For additional information, call CISCRP at 877-633-4376 x 321, or email medheroevents@ciscrp.org.
The Med Hero Appreci-a-thon challenges participants to exercise and support educational initiatives to help patients and their families taking part in clinical trials.
ABOUT CISCRP:
The Center for Information and Study on Clinical Research Participation (CISCRP) is a 501(c)(3) non-profit organization dedicated to engaging the public and patients as partners in the clinical research process. CISCRP provides free education and outreach to the general public and patient communities. Visit www.CISCRP.org for more information and to support CISCRP’s educational initiatives.
Media Contact:
Jim Keen, CISCRP
Phone: 617-725-2750 x330 jkeen@ciscrp.org
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.